Pharmacokinetics and Safety of BI 695502 in Healthy Subjects: a Randomized, Single-blind, Single-dose, Parallel-arm, Active-comparator Clinical Phase I Study
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2016
At a glance
- Drugs Bevacizumab (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Pharmacokinetics
- Acronyms INVICTAN-1
- 16 Nov 2016 According to Boehringer Ingelheim Pharmaceuticals media release, data from this trial were presented at the American Association of Pharmaceutical Scientists Annual Meeting.
- 16 Nov 2016 Results published in a Boehringer Ingelheim Pharmaceuticals media release.
- 08 Feb 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.